Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28

References

• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 74; http://dx.doi.org/10.1038/nrd3229; PMID: 20811384
   PubMed Web of Science ®Google Scholar
• Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24:2 - 11; http://dx.doi.org/10.1111/j.1432-2277.2010.01176.x; PMID: 20964725
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907 - 15; http://dx.doi.org/10.1056/NEJMoa035075; PMID: 14614165
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, et al, Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770 - 81; http://dx.doi.org/10.1056/NEJMoa050085; PMID: 16120857
   PubMed Web of Science ®Google Scholar
• Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, Tillou X, Wu G, Reneaudin K, Hervouet J, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2:17ra10; http://dx.doi.org/10.1126/scitranslmed.3000116; PMID: 20371478
   PubMed Web of Science ®Google Scholar
• Poirier N, Mary C, Dilek N, Hervouet J, Minault D, Blancho G, Vanhove B. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab’ antibody. Am J Transplant 2012; 12:2630 - 40; http://dx.doi.org/10.1111/j.1600-6143.2012.04164.x; PMID: 22759318
   PubMed Web of Science ®Google Scholar
• Poirier N, Blancho G, Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models?. Am J Transplant 2012; 12:1682 - 90; http://dx.doi.org/10.1111/j.1600-6143.2012.04032.x; PMID: 22471377
   PubMed Web of Science ®Google Scholar
• Zhang T, Fresnay S, Welty E, Sangrampurkar N, Rybak E, Zhou H, Cheng X-F, Feng Q, Avon C, Laaris A, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11:1599 - 609; http://dx.doi.org/10.1111/j.1600-6143.2011.03624.x; PMID: 21749640
   PubMed Web of Science ®Google Scholar
• Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P, Haspot F, Tiollier J, Soulillou J-P. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102:564 - 70; http://dx.doi.org/10.1182/blood-2002-08-2480; PMID: 12649149
   PubMed Web of Science ®Google Scholar
• Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, Soulillou J-P, Vanhove B. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99:2228 - 34; http://dx.doi.org/10.1182/blood.V99.6.2228; PMID: 11877302
   PubMed Web of Science ®Google Scholar
• Li J, Semple K, Suh W-K, Liu C, Chen F, Blazar BR, Yu X-Z. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow Transplant 2011; 17:962 - 9; http://dx.doi.org/10.1016/j.bbmt.2011.01.018; PMID: 21447398
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111 - 22; http://dx.doi.org/10.1016/j.immuni.2007.05.016; PMID: 17629517
   PubMed Web of Science ®Google Scholar
• Butte MJ, Peña-Cruz V, Kim M-J, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45:3567 - 72; http://dx.doi.org/10.1016/j.molimm.2008.05.014; PMID: 18585785
   PubMed Web of Science ®Google Scholar
• Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, Broadwater M, Ruff W, Flies S, Xu H, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729 - 40; http://dx.doi.org/10.1016/j.immuni.2011.03.014; PMID: 21530327
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018 - 28; http://dx.doi.org/10.1056/NEJMoa063842; PMID: 16908486
   PubMed Web of Science ®Google Scholar
• Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197:955 - 66; http://dx.doi.org/10.1084/jem.20021024; PMID: 12707299
   PubMed Web of Science ®Google Scholar
• Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83:304 - 13; http://dx.doi.org/10.1097/01.tp.0000251426.46312.d5; PMID: 17297405
   PubMed Web of Science ®Google Scholar
• Mary C, Coulon F, Poirier N, Dilek N, Martinet B, Blancho G, Vanhove B. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain. MAbs 2013; 5:47 - 55; http://dx.doi.org/10.4161/mabs.22697; PMID: 23221503
   PubMed Web of Science ®Google Scholar
• Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161:512 - 26; http://dx.doi.org/10.1111/j.1476-5381.2010.00922.x; PMID: 20880392
   PubMed Web of Science ®Google Scholar
• Pallardy M, Hünig T. Primate testing of TGN1412: right target, wrong cell. Br J Pharmacol 2010; 161:509 - 11; http://dx.doi.org/10.1111/j.1476-5381.2010.00925.x; PMID: 20880391
   PubMed Web of Science ®Google Scholar
• Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, Axthelm MK, Picker LJ. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168:29 - 43; PMID: 11751943
   PubMed Web of Science ®Google Scholar
• Findlay L, Eastwood D, Stebbings R, Sharp G, Mistry Y, Ball C, Hood J, Thorpe R, Poole S. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods 2010; 352:1 - 12; http://dx.doi.org/10.1016/j.jim.2009.10.013; PMID: 19895813
   PubMed Web of Science ®Google Scholar
• Stebbings R, Findlay L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I, et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179:3325 - 31; PMID: 17709549
   PubMed Web of Science ®Google Scholar
• Stebbings R, Eastwood D, Poole S, Thorpe R. After TGN1412: recent developments in cytokine release assays. J Immunotoxicol 2013; 10:75 - 82; http://dx.doi.org/10.3109/1547691X.2012.711783; PMID: 22967038
   PubMed Web of Science ®Google Scholar
• Vidal J-M, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, Mueller-Berghaus J, Pallardy M, Van der Laan J-W. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 2010; 51:213 - 5; http://dx.doi.org/10.1016/j.cyto.2010.04.008; PMID: 20471854
   PubMedGoogle Scholar
• Findlay L, Eastwood D, Ball C, Robinson CJ, Bird C, Wadhwa M, Thorpe SJ, Thorpe R, Stebbings R, Poole S. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 2011; 371:134 - 42; http://dx.doi.org/10.1016/j.jim.2011.06.022; PMID: 21741383
   PubMed Web of Science ®Google Scholar
• Findlay L, Sharp G, Fox B, Ball C, Robinson CJ, Bird C, Stebbings R, Eastwood D, Wadhwa M, Poole S, et al. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 2011; 55:141 - 51; http://dx.doi.org/10.1016/j.cyto.2011.03.019; PMID: 21493088
   PubMed Web of Science ®Google Scholar
• Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010; 2:233 - 55; http://dx.doi.org/10.4161/mabs.2.3.11782; PMID: 20421713
   PubMed Web of Science ®Google Scholar
• Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, Thorpe SJ, Wadhwa M, Thorpe R, Stebbings R. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol 2013; 76:299 - 315; http://dx.doi.org/10.1111/bcp.12165; PMID: 23701319
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007; 6:120 - 6; http://dx.doi.org/10.1038/nrd2242; PMID: 17268483
   PubMed Web of Science ®Google Scholar
• Ohresser M, Olive D, Vanhove B, Watier H. Risk in drug trials. Lancet 2006; 368:2205 - 6; http://dx.doi.org/10.1016/S0140-6736(06)69883-8; PMID: 17189022
   PubMed Web of Science ®Google Scholar
• Hanke T. Lessons from TGN1412. Lancet 2006; 368:1569 - 70, author reply 1570; http://dx.doi.org/10.1016/S0140-6736(06)69651-7; PMID: 17084746
   PubMed Web of Science ®Google Scholar
• Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, Gunzer M, Reichardt P, Kalinke U, Schraven B. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 2008; 3:e1708.
   Google Scholar
• Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A 2006; 103:7765 - 70; http://dx.doi.org/10.1073/pnas.0510484103; PMID: 16682635
   PubMed Web of Science ®Google Scholar
• Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H, et al. A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J Immunol 2013; 191:4599 - 610; http://dx.doi.org/10.4049/jimmunol.1300470; PMID: 24081989
   PubMed Web of Science ®Google Scholar
• Weissmüller S, Semmler LY, Kalinke U, Christians S, Müller-Berghaus J, Waibler Z. ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation. Blood 2012; 119:6268 - 77; http://dx.doi.org/10.1182/blood-2011-12-401083; PMID: 22577174
   PubMed Web of Science ®Google Scholar
• Devallière J, Chatelais M, Fitau J, Gérard N, Hulin P, Velazquez L, Turner CE, Charreau B. LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α-parvin to control cell adhesion and migration. FASEB J 2012; 26:2592 - 606; http://dx.doi.org/10.1096/fj.11-193383; PMID: 22441983
   PubMed Web of Science ®Google Scholar
• www.primateportal.org/normative-values.
   Google Scholar